At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
TAK-931 PIC +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label Study to Assess the Relative Bioavailability, Effect of Food, and Gastric pH Modification on the Pharmacokinetics of TAK-931 in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating TAK-931 PIC, TAK-931 Tablet, and 1 other intervention for Neoplasms, Advanced Solid. Completed, enrolled 20 participants across 4 sites.
Detailed Summary
The purpose of this study is to estimate the relative bioavailability of TAK-931 tablets in reference to powder-in capsule (PIC) and to assess the effect of food and esomeprazole on the pharmacokinetics (PK) of TAK-931 as a tablet.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Advanced Solid
CountriesNetherlands
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartMar 2019
Primary CompletionDec 2019
TodayJul 2026
First PostedOct 17, 2018
Enrollment StartMar 28, 2019
Primary CompletionDec 3, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.7 years ago
Interventions
TAK-931 PICdrug
TAK-931 PICs.
TAK-931 Tabletdrug
TAK-931 Tablets.
Esomeprazoledrug
Esomeprazole Tablets.